

Audit Review Table						
Lovelace Health System, Inc. d.b.a. Lovelace Health Plan (Org ID: 25, SubID: 4000, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2012						
The Auditor lock has been applied to this submission.						
Pharmacy Reversal - Pharmacy Reversals NOT Included						
Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	70.02%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				32.12%	R	Reportable
<i>Counseling for Nutrition</i>				34.55%	R	Reportable
<i>Counseling for Physical Activity</i>				32.36%	R	Reportable
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				87.10%	R	Reportable
<i>IPV</i>				95.86%	R	Reportable
<i>MMR</i>				92.94%	R	Reportable
<i>HiB</i>				96.35%	R	Reportable
<i>Hepatitis B</i>				93.67%	R	Reportable
<i>VZV</i>				92.46%	R	Reportable
<i>Pneumococcal Conjugate</i>				85.40%	R	Reportable
<i>Hepatitis A</i>				88.56%	R	Reportable
<i>Rotavirus</i>				82.24%	R	Reportable
<i>Influenza</i>				63.26%	R	Reportable
<i>Combination #2</i>				81.51%	R	Reportable
<i>Combination #3</i>				77.62%	R	Reportable
<i>Combination #4</i>				73.72%	R	Reportable
<i>Combination #5</i>				70.56%	R	Reportable
<i>Combination #6</i>				54.01%	R	Reportable
<i>Combination #7</i>				66.91%	R	Reportable
<i>Combination #8</i>				52.07%	R	Reportable
<i>Combination #9</i>				50.36%	R	Reportable
<i>Combination #10</i>				48.42%	R	Reportable
Immunizations for Adolescents (ima)	Y					

<i>Meningococcal</i>				60.05%	R	Reportable
<i>Tdap/Td</i>				85.86%	R	Reportable
<i>Combination #1</i>				58.81%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hpv)	Y			17.76%	R	Reportable
Lead Screening in Children (lsc)	Y		N	28.88%	R	Reportable
Breast Cancer Screening (bcs)	Y			40.63%	R	Reportable
Cervical Cancer Screening (ccs)	Y			68.03%	R	Reportable
Chlamydia Screening in Women (chl)	Y					
<i>16-20 Years</i>				38.67%	R	Reportable
<i>21-24 Years</i>				55.59%	R	Reportable
<i>Total</i>				44.09%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		70.36%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	Y		86.54%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		13.67%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			29.67%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
<i>Systemic Corticosteroid</i>				64.29%	R	Reportable
<i>Bronchodilator</i>				91.07%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
<i>5-11 Years</i>				90.13%	R	Reportable
<i>12-18 Years</i>				85.68%	R	Reportable
<i>19-50 Years</i>				72.05%	R	Reportable
<i>51-64 Years</i>				71.05%	R	Reportable
<i>Total</i>				85.44%	R	Reportable
Medication Management for People With Asthma (mma)	Y	Y				

5-11 Years - Medication Compliance 50%				41.83%	R	Reportable
5-11 Years - Medication Compliance 75%				18.13%	R	Reportable
12-18 Years - Medication Compliance 50%				32.83%	R	Reportable
12-18 Years - Medication Compliance 75%				13.68%	R	Reportable
19-50 Years - Medication Compliance 50%				58.62%	R	Reportable
19-50 Years - Medication Compliance 75%				33.62%	R	Reportable
51-64 Years - Medication Compliance 50%				NA	R	Denominator fewer than 30
51-64 Years - Medication Compliance 75%				NA	R	Denominator fewer than 30
Total - Medication Compliance 50%				41.48%	R	Reportable
Total - Medication Compliance 75%				19.20%	R	Reportable
Asthma Medication Ratio (amr)	Y	Y				
5-11 Years				64.92%	R	Reportable
12-18 Years				52.89%	R	Reportable
19-50 Years				41.51%	R	Reportable
51-64 Years				36.84%	R	Reportable
Total				56.64%	R	Reportable
Effectiveness of Care: Cardiovascular						
Cholesterol Management for Patients With Cardiovascular Conditions (cmc)	Y		Y			
LDL-C Screening Performed				73.56%	R	Reportable
LDL-C Control (<100 mg/dL)				36.78%	R	Reportable
Controlling High Blood Pressure (cbp)	Y			56.02%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		NA	R	Denominator fewer than 30
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		Y			
Hemoglobin A1c (HbA1c) Testing				83.21%	R	Reportable
HbA1c Poor Control (>9.0%)				43.07%	R	Reportable
HbA1c Control (<8.0%)				48.91%	R	Reportable
HbA1c Control (<7.0%)				NR	NR	Plan chose not to report
Eye Exam (Retinal) Performed				46.72%	R	Reportable
LDL-C Screening Performed				68.37%	R	Reportable
LDL-C Control (<100 mg/dL)				28.47%	R	Reportable

<i>Medical Attention for Nephropathy</i>				74.70%	R	Reportable
<i>Blood Pressure Control (<140/80 mm Hg)</i>				46.96%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>				69.59%	R	Reportable
Effectiveness of Care: Musculoskeletal						
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		64.91%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			80.28%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	N				
<i>Effective Acute Phase Treatment</i>				NB	R	Required benefit not offered
<i>Effective Continuation Phase Treatment</i>				NB	R	Required benefit not offered
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
<i>Initiation Phase</i>				39.00%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>				46.67%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	N				
<i>30-Day Follow-Up</i>				NB	R	Required benefit not offered
<i>7-Day Follow-Up</i>				NB	R	Required benefit not offered
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	N		NB	R	Required benefit not offered
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			NA	R	Denominator fewer than 30
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			NA	R	Denominator fewer than 30
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	N		NB	R	Required benefit not offered

Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
<i>ACE Inhibitors or ARBs</i>				86.70%	R	Reportable
<i>Digoxin</i>				NA	R	Denominator fewer than 30
<i>Diuretics</i>				84.65%	R	Reportable
<i>Anticonvulsants</i>				67.76%	R	Reportable
<i>Total</i>				83.44%	R	Reportable
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
<i>20-44 Years</i>				82.45%	R	Reportable
<i>45-64 Years</i>				85.30%	R	Reportable
<i>65+ Years</i>				87.50%	R	Reportable
<i>Total</i>				83.15%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
<i>12-24 Months</i>				98.55%	R	Reportable
<i>25 Months - 6 Years</i>				88.77%	R	Reportable
<i>7-11 Years</i>				91.82%	R	Reportable
<i>12-19 Years</i>				90.88%	R	Reportable
Annual Dental Visit (adv)	Y	Y				
<i>2-3 Years</i>				56.58%	R	Reportable
<i>4-6 Years</i>				75.98%	R	Reportable
<i>7-10 Years</i>				79.80%	R	Reportable
<i>11-14 Years</i>				74.54%	R	Reportable
<i>15-18 Years</i>				64.11%	R	Reportable
<i>19-21 Years</i>				44.03%	R	Reportable
<i>Total</i>				71.49%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	N				
<i>Initiation of AOD Treatment: 13-17 Years</i>				NB	R	Required benefit not offered
<i>Engagement of AOD Treatment: 13-17 Years</i>				NB	R	Required benefit not offered
<i>Initiation of AOD Treatment: 18+ Years</i>				NB	R	Required benefit not offered

<i>Engagement of AOD Treatment: 18+ Years</i>				NB	R	Required benefit not offered
<i>Initiation of AOD Treatment: Total</i>				NB	R	Required benefit not offered
<i>Engagement of AOD Treatment: Total</i>				NB	R	Required benefit not offered
Prenatal and Postpartum Care (ppc)	Y					
<i>Timeliness of Prenatal Care</i>				87.06%	R	Reportable
<i>Postpartum Care</i>				65.50%	R	Reportable
Call Answer Timeliness (cat)	Y			88.29%	R	Reportable
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<i><21 Percent</i>				10.51%	R	Reportable
<i>21-40 Percent</i>				6.20%	R	Reportable
<i>41-60 Percent</i>				5.66%	R	Reportable
<i>61-80 Percent</i>				12.67%	R	Reportable
<i>81+ Percent</i>				64.96%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Y		Y			
<i>0 Visits</i>				0.77%	R	Reportable
<i>1 Visit</i>				1.55%	R	Reportable
<i>2 Visits</i>				1.29%	R	Reportable
<i>3 Visits</i>				2.58%	R	Reportable
<i>4 Visits</i>				10.57%	R	Reportable
<i>5 Visits</i>				15.98%	R	Reportable
<i>6+ Visits</i>				67.27%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		Y	64.97%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N	41.95%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	N				NR	Measure Unselected
Ambulatory Care: Disabled (ambc)	N				NR	Measure Unselected
Ambulatory Care: Other (ambd)	N				NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)	Y				R	Reportable

Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	N				NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)	N				NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)	N				NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Total (iada)	Y	N			R	Required benefit not offered
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N			NR	Measure Unselected
Mental Health Utilization: Total (mpta)	Y	N			R	Required benefit not offered
Mental Health Utilization: Dual Eligibles (mptb)	N	N			NR	Measure Unselected
Mental Health Utilization: Disabled (mptc)	N	N			NR	Measure Unselected
Mental Health Utilization: Other (mptd)	N	N			NR	Measure Unselected
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	N	N			NR	Measure Unselected
Antibiotic Utilization: Disabled (abxc)	N	N			NR	Measure Unselected
Antibiotic Utilization: Other (abxd)	N	N			NR	Measure Unselected
Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	Y				R	Reportable
Relative Resource Use for People With Asthma (ras)	Y	Y			R	Reportable
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R	Reportable
Relative Resource Use for People With Hypertension (rhy)	Y				R	Reportable
Relative Resource Use for People With COPD (rco)	Y				R	Reportable

Health Plan Descriptive Information						
Board Certification (bcr)	Y				R	Reportable
Total Membership (tln)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	Y				R	Reportable
Enrollment by Product Line: Disabled (enpc)	Y				R	Reportable
Enrollment by Product Line: Other (enpd)	Y				R	Reportable
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Y				R	Reportable
Language Diversity of Membership (ldm)	Y				R	Reportable
Weeks of Pregnancy at Time of Enrollment in MCO (wop)	Y				R	Reportable